Astragalus
TL;DR
Premier Qi tonic from the Shen Nong Ben Cao Jing. Astragalus membranaceus with two key actives: Astragaloside IV (saponin) and Cycloastragenol (TA-65 — the aglycone). TA-65 is the most clinically validated telomerase activator in humans (SMD=0.47, p<0.00001, meta-analysis of 8 RCTs, n=750). Also provides foundational hematopoietic support; protects bone marrow from chemo/radiation; AMPK activation restores autophagic flux.
Why it matters for Vitals
Astragalus is the most evidence-backed natural telomerase activator available. Telomere length is a legitimate aging biomarker — the TA-65 meta-analysis is robust. The hematopoietic support is directly relevant to endurance athletes and anyone with compromised bone marrow function (chronic stress, overtraining). Combining with Rapamycin provides complementary AMPK/mTOR modulation without over-suppressing growth pathways.
Key Facts
| Status | OTC; not scheduled |
| Class | TCM Superior Herb — Qi tonic |
| Primary mechanism | Astragaloside IV → Cycloastragenol → transient TERT upregulation → telomere elongation |
| Key benefits | Telomere elongation (TA-65 meta-analysis), hematopoietic support, bone marrow protection, NSCLC survival adjunct |
| Dosing | 1,000–2,000 mg/day (hot water extract); or 10–50 mg/day TA-65 |
| Timing | Morning, empty stomach — maximizes immunomodulatory absorption |
| Cycling | 12 weeks on, 4 weeks off — pulsing prevents immune receptor downregulation |
| Main risks | CONTRAINDICATED with immunosuppressants post-transplant; may potentiate hypoglycemics/diuretics |
| Evidence level | Strong — TA-65 meta-analysis (8 RCTs, n=750); Astragalus + NSCLC meta-analysis (65 RCTs, n=4,751) |
Mechanism Summary
Telomerase activation: Astragaloside IV → metabolized to Cycloastragenol (TA-65) → transient TERT upregulation → telomere elongation in leukocytes.
TA-65 meta-analysis (8 RCTs, n=750, mean age 63.3):
- Moderate statistically significant leukocyte telomere length (LTL) elongation
- SMD = 0.47 (p < 0.00001)
- Age >60 amplified effect: SMD = 0.63
- No oncogenesis risk or severe adverse events
Critical limitation: Short-term telomere elongation does NOT immediately translate to functional frailty improvements (grip strength, 6-minute walk) or hs-CRP/IL-6 reduction. Underscores necessity of synergistic multi-herb approach.
Hematopoietic support: APS (Astragalus polysaccharides) → TLR signaling → macrophage/dendritic cell maturation → innate immune priming.
Bone marrow protection: Actively protects hematopoietic cells from chemotherapy/radiation-induced myelosuppression (relevant for cancer patients and extreme physical stressors).
AMPK activation: Restores autophagic flux in metabolically compromised tissues.
Clinical Evidence
TA-65 / Astragaloside IV:
- Meta-analysis (8 RCTs, n=750): LTL elongation SMD=0.47 (p<0.00001); age>60: SMD=0.63
NSCLC (as chemotherapy adjuvant):
- Meta-analysis (65 RCTs, n=4,751): Astragalus + platinum chemo → 6-month survival RR=0.54 (p≤0.0001); 12-month RR=0.65 (p≤0.0001); ↓ myelosuppression + nausea
Drug Interactions
| Drug | Interaction |
|---|---|
| Immunosuppressants (cyclosporine, corticosteroids) | CONTRAINDICATED — immune stimulation may cause transplant rejection |
| Insulin, metformin | Additive hypoglycemic — monitor glucose closely |
| Diuretics, blood pressure medications | Monitor |
Inside this hub
- Calycosin (flavonoid) specifics — too secondary
- APS-I vs APS-II distinction — kept here, not split
- Detailed TLR subunit signaling cascade — too granular
Related notes
- TCM Superior Herbs — parent system
- Telomerase — shared telomere mechanism; links to TA-65 evidence
- Rapamycin — comparison: mTOR inhibition; Astragalus = AMPK activation without immune suppression
- Cordyceps — comparison: both Qi tonics, AMPK; Cordyceps = ATP/VO2, Astragalus = TERT/hematopoietic
- Mitophagy — comparison: Astragalus AMPK overlap with Cordyceps/He Shou Wu
- Immune modulation — APS macrophage/dendritic priming